
South Korea’S Celltrion Expects Minimal Impact From Trump's Drug Pricing Order
(MENAFN- IANS) Seoul, May 15 (IANS) Celltrion, a leading South Korean biopharmaceutical company, on Thursday said its business will remain largely unaffected by US President Donald Trump's executive order aimed at lowering drug prices to match those in …